Published in Medical Letter on the CDC and FDA, July 4th, 2004
Dyax recently announced that DX-88 clinical studies were placed on clinical hold by the FDA for reasons unrelated to observations in humans, and pending the agency's further review of preclinical animal data.
This review was promptly conducted, and the clinical hold has been removed. While DX-88 clinical studies continue, Dyax and Genzyme Corporation (GENZ) will collaborate closely with the FDA to design additional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.